BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

576 related articles for article (PubMed ID: 34155513)

  • 1. Oncologic and survival outcomes in elderly patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy and total mesorectal excision.
    He F; Chen M; Xiao WW; Zhang Q; Liu Y; Zheng J; Wan XB; Gao YH
    Jpn J Clin Oncol; 2021 Aug; 51(9):1391-1399. PubMed ID: 34155513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant Chemotherapy Does Not Improve Recurrence-Free Survival in Patients With Stage 2 or Stage 3 Rectal Cancer After Neoadjuvant Chemoradiotherapy and Total Mesorectal Excision.
    Voss RK; Lin JC; Roper MT; Al-Temimi MH; Ruan JH; Tseng WH; Tam M; Sherman MJ; Klaristenfeld DD; Tomassi MJ
    Dis Colon Rectum; 2020 Apr; 63(4):427-440. PubMed ID: 31996583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evaluation of progression-free survival for locally advanced rectal cancer by MRI after neoadjuvant chemoradiotherapy and total mesorectal excision].
    Zhang JX; Yang Z; Fan P; Zhang JJ; Xin L; Hou LN; Du XS; Yang XT
    Zhonghua Zhong Liu Za Zhi; 2018 Feb; 40(2):121-126. PubMed ID: 29502372
    [No Abstract]   [Full Text] [Related]  

  • 4. Timing of additional neoadjuvant chemotherapy in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy and total mesorectal excision.
    He F; Chen M; Liu YP; Sun J; Zheng J
    Discov Oncol; 2022 Oct; 13(1):111. PubMed ID: 36271070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncologic outcomes after neoadjuvant chemoradiation followed by curative resection with tumor-specific mesorectal excision for fixed locally advanced rectal cancer: Impact of postirradiated pathologic downstaging on local recurrence and survival.
    Kim NK; Baik SH; Seong JS; Kim H; Roh JK; Lee KY; Sohn SK; Cho CH
    Ann Surg; 2006 Dec; 244(6):1024-30. PubMed ID: 17122629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncologic Outcome and Morbidity in the Elderly Rectal Cancer Patients After Preoperative Chemoradiotherapy and Total Mesorectal Excision: A Multi-institutional and Case-matched Control Study.
    Sung SY; Jang HS; Kim SH; Jeong JU; Jeong S; Song JH; Chung MJ; Cho HM; Kim HJ; Kim JG; Lee IK; Lee JH
    Ann Surg; 2019 Jan; 269(1):108-113. PubMed ID: 28742692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Outcomes of Local Excision Following Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer.
    D'Alimonte L; Bao QR; Spolverato G; Capelli G; Del Bianco P; Albertoni L; De Paoli A; Guerrieri M; Mantello G; Gambacorta MA; Canzonieri V; Valentini V; Coco C; Pucciarelli S
    Ann Surg Oncol; 2021 May; 28(5):2801-2808. PubMed ID: 33125570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. mFOLFOXIRI versus mFOLFOX6 as neoadjuvant chemotherapy in locally advanced rectal cancer: A Propensity Score Matching Analysis.
    Ding M; Zhang J; Hu H; Cai Y; Ling J; Wu Z; Xie X; Li J; Li W; Deng Y
    Clin Colorectal Cancer; 2022 Mar; 21(1):e12-e20. PubMed ID: 34963563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
    Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
    BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of chemoradiotherapy on recurrence and survival in locally advanced rectal cancers with curative total mesorectal excision: a prospective, nonrandomized study.
    Akgun E; Ozkok S; Tekin M; Yoldas T; Caliskan C; Kose T; Karabulut B; Sezak M; Elmas N; Ozutemiz O
    World J Surg Oncol; 2017 Nov; 15(1):205. PubMed ID: 29166925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonmetastatic ypt0 rectal cancer after neoadjuvant treatment and total mesorectal excision: Lessons from a retrospective multicentric cohort of 383 patients.
    Collard MK; Rullier E; Panis Y; Manceau G; Benoist S; Tuech JJ; Alves A; Laforest A; Mege D; Cazelles A; Beyer-Berjot L; Christou N; Cotte E; Lakkis Z; O'Connell L; Parc Y; Piessen G; Lefevre JH;
    Surgery; 2022 May; 171(5):1193-1199. PubMed ID: 35078629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of neoadjuvant chemoradiotherapy followed by total mesorectal excision surgery for locally advanced rectal cancer: a single-institution experience.
    Tseng MSF; Zheng H; Ng IWS; Leong YH; Leong CN; Yong WP; Cheong WK; Tey JCS
    Singapore Med J; 2018 Jun; 59(6):305-310. PubMed ID: 29167909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Organ preservation with chemoradiotherapy plus local excision for rectal cancer: 5-year results of the GRECCAR 2 randomised trial.
    Rullier E; Vendrely V; Asselineau J; Rouanet P; Tuech JJ; Valverde A; de Chaisemartin C; Rivoire M; Trilling B; Jafari M; Portier G; Meunier B; Sieleznieff I; Bertrand M; Marchal F; Dubois A; Pocard M; Rullier A; Smith D; Frulio N; Frison E; Denost Q
    Lancet Gastroenterol Hepatol; 2020 May; 5(5):465-474. PubMed ID: 32043980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does Adjuvant Chemotherapy for Locally Advanced Resectable Rectal Cancer treated with Neoadjuvant Chemoradiotherapy have an impact on survival? A Single Moroccan Institute Retrospective Study.
    Seddik Y; Brahmi SA; Afqir S
    Gulf J Oncolog; 2019 May; 1(30):29-32. PubMed ID: 31242979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ACRNaCT trial protocol: efficacy of adjuvant chemotherapy in patients with clinical T3b/T4, N+ rectal Cancer undergoing Neoadjuvant Chemoradiotherapy: a pathology-oriented, prospective, multicenter, randomized, open-label, parallel group clinical trial.
    Li Q; Luo D; Zhu J; Yang L; Liu Q; Ma Y; Liang L; Cai S; Zhang Z; Li X;
    BMC Cancer; 2019 Nov; 19(1):1117. PubMed ID: 31729964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival After Induction Chemotherapy and Chemoradiation Versus Chemoradiation and Adjuvant Chemotherapy for Locally Advanced Rectal Cancer.
    Kim JK; Marco MR; Roxburgh CSD; Chen CT; Cercek A; Strombom P; Temple LKF; Nash GM; Guillem JG; Paty PB; Yaeger R; Stadler ZK; Gonen M; Segal NH; Reidy DL; Varghese A; Shia J; Vakiani E; Wu AJ; Romesser PB; Crane CH; Gollub MJ; Saltz L; Smith JJ; Weiser MR; Patil S; Garcia-Aguilar J
    Oncologist; 2022 May; 27(5):380-388. PubMed ID: 35278070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting survival in locally advanced rectal cancer with effective chemoradiotherapy response.
    Kim S; Huh JW; Lee WY; Yun SH; Kim HC; Cho YB; Park Y; Shin JK
    Eur J Surg Oncol; 2024 Jun; 50(6):108361. PubMed ID: 38657375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison of long-term efficacy between watch and wait strategy and total mesorectal excision in locally advanced rectal cancer patients with clinical complete response after neoadjuvant therapy].
    Wang XH; Zhou CJ; Zhang S; Wang QX; Xiao WW; Ding PR; Chen G; Pan ZZ; Zeng ZF; Gao YH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):266-273. PubMed ID: 32192306
    [No Abstract]   [Full Text] [Related]  

  • 19. Long-term prognostic value of mesorectal grading after neoadjuvant chemoradiotherapy for rectal cancer.
    Madbouly KM; Hussein AM; Abdelzaher E
    Am J Surg; 2014 Sep; 208(3):332-41. PubMed ID: 24581995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adding Induction Chemotherapy Before Chemoradiotherapy with Total Mesorectal Excision and Selective Lateral Lymph Node Dissection for Patients with Poor-Risk, Locally Advanced, Mid-to-Low Rectal Cancer May Improve Oncologic Outcomes: A Propensity Score-Matched Analysis.
    Yamaguchi T; Akiyoshi T; Fukunaga Y; Sakamoto T; Mukai T; Hiyoshi Y; Nagasaki T; Taguchi S; Chino A; Shinozaki E; Yamaguchi K; Konishi T
    Ann Surg Oncol; 2023 Aug; 30(8):4716-4724. PubMed ID: 37032405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.